Robert K Suter
Overview
Explore the profile of Robert K Suter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chowdary R, Suter R, DAntuono M, Gomes C, Stein J, Lee K, et al.
bioRxiv
. 2024 Dec;
PMID: 39651293
Single-cell and spatial transcriptomics provide unprecedented insight into the inner workings of disease. Pharmacotranscriptomic approaches are powerful tools that leverage gene expression data for drug repurposing and treatment discovery in...
2.
Veeramachaneni R, Suter R, Rowland E, Jermakowicz A, Ayad N
Biochim Biophys Acta Rev Cancer
. 2024 Sep;
1879(6):189182.
PMID: 39293549
Glioblastoma (GBM) is the most common malignant primary adult brain tumor. Despite standard-of-care treatment, which consists of surgical resection, temozolomide (TMZ) treatment, and radiotherapy, the prognosis for GBM patients remains...
3.
Rodriguez-Blanco J, Salvador A, Suter R, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, et al.
J Clin Invest
. 2024 Jun;
134(15).
PMID: 38885332
Most children with medulloblastoma (MB) achieve remission, but some face very aggressive metastatic tumors. Their dismal outcome highlights the critical need to advance therapeutic approaches that benefit such high-risk patients....
4.
Malchiodi Z, Suter R, Deshpande A, Peran I, Harris B, Duttargi A, et al.
bioRxiv
. 2024 Jun;
PMID: 38853982
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. PDAC's poor prognosis and resistance to immunotherapy are attributed in part to its dense, fibrotic tumor microenvironment...
5.
Jermakowicz A, Kurimchak A, Johnson K, Bourgain-Guglielmetti F, Kaeppeli S, Affer M, et al.
Sci Rep
. 2024 Apr;
14(1):9284.
PMID: 38654040
Bromodomain and extra-terminal domain (BET) proteins are therapeutic targets in several cancers including the most common malignant adult brain tumor glioblastoma (GBM). Multiple small molecule inhibitors of BET proteins have...
6.
Shah A, Rivas S, Doucet-OHare T, Govindarajan V, DeMarino C, Wang T, et al.
J Clin Invest
. 2023 Jul;
133(13).
PMID: 37395282
Human endogenous retroviruses (HERVs) are ancestral viral relics that constitute nearly 8% of the human genome. Although normally silenced, the most recently integrated provirus HERV-K (HML-2) can be reactivated in...
7.
Jordan Walter T, Suter R, Ayad N
Neurobiol Dis
. 2023 Jun;
184:106201.
PMID: 37321420
Neurobiological disorders are highly prevalent medical conditions that contribute to significant morbidity and mortality. Single-cell RNA sequencing (scRNA-seq) is a technique that measures gene expression in individual cells. In this...
8.
Yang F, Rodriguez-Blanco J, Long J, Swiderska-Syn M, Wynn D, Li B, et al.
Mol Cancer Res
. 2022 Aug;
20(11):1598-1610.
PMID: 35925047
Implications: This work describes a novel, druggable UHRF1/DNMT1/GLI complex that regulates SHH-dependent tumor growth, and highlights an FDA-approved drug capable of disrupting this complex to attenuate tumor growth.
9.
Govindarajan V, Shah A, Di L, Rivas S, Suter R, Eichberg D, et al.
World Neurosurg
. 2022 Mar;
162:47-56.
PMID: 35314408
Background: Isocitrate dehydrogenase (IDH) mutations are present in 70% of World Health Organization grade II and III gliomas. IDH mutation induces accumulation of the oncometabolite 2-hydroxyglutarate. Therefore, therapies targeting reversal...
10.
Rybin M, Laverde-Paz M, Suter R, Affer M, Ayad N, Feng Y, et al.
Bioorg Med Chem Lett
. 2022 Feb;
61:128614.
PMID: 35151865
High rates of recurrence and treatment resistance in the most common malignant adult brain cancer, glioblastoma (GBM), suggest that monotherapies are not sufficiently effective. Combination therapies are increasingly pursued, but...